amidoxime

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The efficient development of selective materials for the recovery of uranium from nuclear waste and seawater is necessary for… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Here we present the first structural comparison of amidoxime complexes of UO2(2+) and VO2(+) (the main competitor in the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
Under high dose treatment with sulfamethoxazole (SMX)/trimethoprim (TMP), hypersensitivity reactions occur with a high incidence… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
2013
2013
The mitochondrial amidoxime reducing component mARC is a recently discovered molybdenum enzyme in mammals. mARC is not active as… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Reduction of hydroxylamines and amidoximes is important for drug activation and detoxification of aromatic and heterocyclic… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2011
2011
NOSs (nitric oxide synthases) catalyse the oxidation of L-arginine to L-citrulline and nitric oxide via the intermediate NOHA (N… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2010
2010
The mitochondrial amidoxime reducing component mARC is a newly discovered molybdenum enzyme that is presumed to form the… (More)
Is this relevant?
2005
2005
Furamidine is an effective antimicrobial agent; however, oral potency of furamidine is poor. A prodrug of furamidine, 2,5-bis(4… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
N-Hydroxylated amidines (amidoximes) can be used as prodrugs of amidines. The prodrug principle was developed in our laboratory… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1996
1996
The potent and selective GP IIb-IIIa antagonist lamifiban (1, Ro 44-9883) is currently in clinical development as an injectable… (More)
Is this relevant?